A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer

Trial Profile

A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Triciribine (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Breast cancer; Male breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TCN-PM
  • Most Recent Events

    • 30 Mar 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov
    • 30 Mar 2015 Status changed from suspended to recruiting as reported by ClinicalTrials.gov
    • 01 Jul 2014 Planned number of patients changed from 46 to 56 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top